福建广生堂药业股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、福建广生堂药业股份有限公司（以下简称"公司"）股票自 2025 年 7 月 29 日至 7 月 31 日连续三个交易日收盘价格涨幅偏离值累计超过 30%。根据《深 圳证券交易所交易规则》规定，属于股票交易异常波动的情况。根据中证指数有 限公司最新数据显示，截至 2025 年 7 月 30 日，公司的最新市净率为 46.58；公 司所属中上协行业分类"医药制造业（C27）"的最新市净率为 3.17。公司市净 率与同行业的情况有较大差异。公司股价短期内大幅上涨，但公司基本面未发生 重大变化，可能存在股价大幅上涨后回落的风险，郑重提醒广大投资者注意公司 股票二级市场交易风险，理性决策，谨慎投资。 2、公司最近三年及一期经营业绩连续亏损。公司 2022 年至 2025 年第一季 度归属于上市公司股东的净利润分别为-12,740.39 万元、-34,858.98 万元、 -15,630.44 万元，-2,848.89 万元。敬请广大投资者注意投资风险， ...

Core Viewpoint - The company's stock price has experienced a significant increase, with a cumulative rise of over 30% over three consecutive trading days, indicating abnormal trading fluctuations [1] Company Summary - The company's latest price-to-book ratio (P/B) is reported at 46.58 as of July 30, 2025 [1] - This P/B ratio is substantially higher than the average P/B ratio of 3.17 for the pharmaceutical manufacturing industry (C27) [1] - Despite the sharp increase in stock price, there have been no significant changes in the company's fundamentals [1] Industry Summary - The pharmaceutical manufacturing industry has an average P/B ratio of 3.17, highlighting a stark contrast with the company's valuation metrics [1]

Group 1 - The core point of the article highlights the performance of A-share stocks in July, with significant gains observed in specific companies [1] - The top performer, Aowei New Materials, achieved a cumulative increase of 1083.42% in July, ranking first among A-share stocks [1] - Guangsheng Tang ranked second with a cumulative increase of 218.94% during the same period [1]

Core Viewpoint - The assisted reproduction sector has shown a positive performance with a 1.72% increase, ranking third among concept sectors, driven by significant gains in several stocks [1][2]. Group 1: Sector Performance - As of July 31, the assisted reproduction concept increased by 1.72%, with 34 stocks rising, including Anke Bio and Gongtong Pharmaceutical, which both hit the 20% limit up [1]. - Notable gainers in the sector included Guangshengtang, Xinghao Pharmaceutical, and Hanyu Pharmaceutical, with increases of 18.04%, 8.03%, and 7.02% respectively [1]. - Conversely, stocks such as Jiabiyou, Changchun High-tech, and Zhejiang Medicine experienced declines of 3.70%, 3.02%, and 2.99% respectively [1]. Group 2: Capital Flow - The assisted reproduction sector saw a net inflow of 0.18 billion yuan, with 30 stocks receiving net inflows from major funds [2]. - Anke Bio led the sector with a net inflow of 4.09 billion yuan, followed by Zhongsheng Pharmaceutical and Hanshang Group with net inflows of 2.04 billion yuan and 1.44 billion yuan respectively [2]. - The top three stocks by net inflow ratio were Hanshang Group at 53.93%, Lideman at 35.62%, and Gongtong Pharmaceutical at 23.90% [3].

证券之星消息，7月31日化学制药板块较上一交易日下跌0.23%，灵康药业领跌。当日上证指数报收于 3573.21，下跌1.18%。深证成指报收于11009.77，下跌1.73%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688189 | 南新制药 | 17.14 | 20.03% | 34.06万 | | 5.59亿 | | 300966 | 并同药业 | 24.61 | 19.99% | 12.63万 | | 2.966Z | | 300436 | 广生堂 | 114.50 | 18.04% | 21.98万 | | 24.15 Z | | 300204 | 舒泰神 | 51.99 | 10.55% | 1 29.99万 | | 15.11亿 | | 603229 | 奧翔药业 | 11.61 | 10.05% | 110.20万 | | 12.53亿 | | 002940 | 昂利康 | 57.20 | 10.00% | 20.97万 | ...

Market Performance - The three major A-share indices all recorded gains in July, with the Shanghai Composite Index rising by 3.74% to close at 3573 points, marking a three-month consecutive increase [1] - The Shenzhen Component Index increased by 5.2% to 11009 points, while the ChiNext Index surged by 8.14% to 2328 points [1] Sector Performance - The top five performing sectors over the past 20 trading days were: - Hydropower concept up 27.35% - Tibet sector up 25.85% - Engineering machinery up 19.88% - Medical services up 18.17% - CRO concept up 17.36% [2] - Conversely, the five sectors with the largest declines were: - Insurance down 6.27% - Precious metals down 3.57% - Banking down 3.41% - Guangdong Free Trade Zone down 2.23% - Food processing and manufacturing down 1.36% [2] Individual Stock Performance - The top five individual stocks in terms of gains for July were: - Shangwei New Materials up 1083.42% - N Dingjia up 479.12% - C Hanguo up 290.08% - Shanda Power up 228.04% - Guangsheng Tang up 218.94% [2] - The five stocks with the largest declines were: - *ST Zitian down 68.65% - *ST Suwu down 48.02% - *ST Tianmao down 44.16% - Yuandao Communication down 31.83% - ST Yundong down 31.77% [2]

Core Viewpoint - The article highlights a collective rebound in the technology sector, driven by strong performances from Microsoft and Meta, which have ignited interest in the computing power segment and sustained momentum in innovative pharmaceuticals [2][8]. Market Overview - The A-share market showed mixed performance with the Shanghai Composite Index down by 0.68% and the Shenzhen Component Index down by 0.45%, while the ChiNext Index rose by 0.43% [2]. - The total trading volume in the Shanghai and Shenzhen markets exceeded 1.14 trillion yuan, an increase of 562 billion yuan compared to the previous trading day [3]. Technology Sector Performance - Major technology stocks rebounded, with CPO (Cloud Power Optimization), PCB (Printed Circuit Board), and other computing hardware leading the gains. Concepts related to communication and AI also saw renewed activity [3][9]. - CPO concept stocks experienced significant gains, with companies like Ruijie Networks and Cambridge Technology seeing substantial increases in stock prices, with Cambridge Technology hitting the daily limit [10][13]. Innovative Pharmaceuticals - The innovative pharmaceutical sector remained active, with stocks like Nanxin Pharmaceutical and Qizheng Tibetan Medicine hitting the daily limit, indicating strong investor interest [17]. - A report from CITIC Securities suggests that recent policy signals support the development of innovative drugs and medical devices, indicating potential investment opportunities in the medical device sector [22]. Notable Stock Movements - Industrial Fulian's stock surged over 8%, reaching a historical high with a market capitalization of 704.2 billion yuan, surpassing Changjiang Electric Power [15]. - The article also notes significant gains in weight-loss drug stocks, with companies like Anke Bio and Dezheng Health seeing increases of over 6% [20][21].

格隆汇7月31日｜上证指数午盘跌0.68%，创业板指涨0.43%。英伟达产业链全线走强，工业富联携"易 中天"CPO三巨头齐创历史新高；AI应用端、液冷概念开启补涨，创新药反复活跃，舒泰神、广生堂再 创新高；周期股延续调整，钢铁、煤炭、稀土板块齐挫，地产、保险股表现低迷。 ETF方面，AI硬件股全线爆发，创业板人工智能ETF华宝、创业板人工智能ETF国泰、创业板人工智能 ETF富国、创业板人工智能ETF南方涨4%，国泰基金通信ETF、新华基金云50ETF分别涨3.79%、 3.69%。创新药板块延续涨势，华泰柏瑞基金恒生创新药ETF、港股通创新药ETF工银分别涨2.93%、 2.55%。 地产股跌幅居前，房地产ETF、房地产ETF分别跌3.66%、3.06%。周期股延续调整，矿业ETF、钢铁 ETF分别跌3.41%、3.36%。 ...

Group 1 - The core viewpoint of the news is the introduction of a nationwide childcare subsidy program aimed at supporting families with eligible infants born after January 1, 2022, which is expected to stimulate consumption in the maternal and infant sectors [1][2] - The central government has allocated an initial budget of approximately 90 billion yuan for the childcare subsidy program, with the central finance covering about 90% of the funding needed for the basic standard subsidy [2] - The announcement has led to a significant increase in stock prices of companies in the assisted reproduction and maternal-infant sectors, with companies like Gongtong Pharmaceutical and Lide Man reaching a 20% limit-up [1] Group 2 - The subsidy program is described as a major initiative for public welfare, providing direct cash benefits to families regardless of urban or rural status, ethnicity, or the number of children [1] - Short-term effects of the subsidy are expected to directly stimulate consumption in related sectors such as baby care, dairy products, toys, and children's clothing [2] - Long-term implications include an increase in birth rates and improved willingness to have children, which may benefit the entire maternal and infant industry chain, including assisted reproduction, genetic testing, childcare services, and education [2]

Core Viewpoint - The A-share assisted reproductive sector is experiencing significant growth, with multiple companies reaching new highs and notable stock price increases [1] Company Performance - Fuyuan Pharmaceutical reached an all-time high during trading [1] - Gongtong Pharmaceutical, Hanshang Group, and Lide Man all hit the daily limit up [1] - Anke Bio increased by over 15% [1] - Guangshengtang rose by over 10% [1] - Other companies such as Xinguang Pharmaceutical, Dajia Weikang, BeiYinMei, Xinghao Pharmaceutical, and Beirui Gene also saw price increases [1]